- Free from Publisher RA DeFronzo, RE Ratner, J Han, DD Kim, MS … - Diabetes care, 2005 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A triple-blind, placebo-controlled, 30-week study
at 82 US sites was performed with 336 randomized patients. In all, 272 patients
completed the study. The intent-to-treat population baseline was 53 ± 10 ... Cited by 635 - Related articles - All 6 versions
- Free from Publisher DM Kendall, MC Riddle, J Rosenstock, D … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—Week 30 A1C changes from baseline (±SE) were −0.8 ± 0.1% (10 μg),
−0.6 ± 0.1% (5 μg), and +0.2 ± 0.1% (placebo; adjusted P < 0.0001 vs.
placebo), yielding placebo-adjusted reductions of −1.0% (10 μg) and ... Cited by 542 - Related articles - All 11 versions
- ►diabetesjournals.org JB Buse, RR Henry, J Han, DD Kim, MS … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—At week 30, HbA 1c changes from baseline were −0.86 ± 0.11, −0.46
± 0.12, and 0.12 ± 0.09% (±SE) in the 10-μg, 5-μg, and placebo arms,
respectively (adjusted P < 0.001). Of evaluable subjects with baseline HbA ... Cited by 453 - Related articles - BL Direct - All 13 versions
- ►annals.org [PDF] RJ Heine, LF Van Gaal, D Johns, MJ Mihm, … - Annals of internal medicine, 2005 - Am Coll Physicians Patients: 551 patients with type 2 diabetes and inadequate gly- cemic control
(defined as hemoglobin A1c level ranging from 7.0% to 10.0%) despite combination
metformin and sulfonylurea therapy. Intervention: Exenatide, 10 g twice ... Cited by 329 - Related articles - BL Direct - All 7 versions
- ►endojournals.org OG Kolterman, JB Buse, MS Fineman, E Gaines … - Journal of Clinical Endocrinology & Metabolism, 2003 - Endocrine Soc Despite the advent of new treatments, glucose control in the type 2 diabetes
population is unsatisfactory. AC2993 (synthetic exendin-4; exenatide), a novel
glucose-dependent insulinotropic agent, exhibited notable antidiabetic ... Cited by 274 - Related articles - BL Direct - All 6 versions
- ►diabetesjournals.org MS Fineman, TA Bicsak, LZ Shen, K Taylor, E … - Diabetes Care, 2003 - Am Diabetes Assoc RESULTS—All three AC2993 regimens led to significant reductions in serum
fructosamine relative to placebo (P ≤ 0.004). Mean reductions ranged from 39
to 46 μmol/l. All AC2993 groups had reductions in HbA 1c ranging from 0.7 ... Cited by 230 - Related articles - BL Direct - All 10 versions
L Blonde, EJ Klein, J Han, B Zhang, SM Mac, … - Diabetes, Obesity & Metabolism, 2006 - pt.wkhealth.com Results: Patients completed 82 weeks of exenatide treatment [n = 314, 63% M, age
56 ± 10 years, weight 99 ± 21 kg, body mass index 34 ± 6 kg/m 2 , A1C 8.3 ±
1.0% (mean ± SD)]. Reduction in A1C from baseline to week 30 [-0.9 ± 0.1% ... Cited by 172 - Related articles - BL Direct - All 6 versions
- Free from Publisher B Ahrén, R Gomis, E Standl, D Mills, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—In patients randomized to LAF237, baseline HbA 1c averaged 7.7 ± 0.1%
and decreased at week 12 (Δ = −0.6 ± 0.1%), whereas HbA 1c did not change
from a baseline of 7.9 ± 0.1% in patients given placebo (between-group ... Cited by 310 - Related articles - BL Direct - All 8 versions
OG Kolterman, DD Kim, L Shen, JA Ruggles, … - American Journal of Health-System Pharmacy, 2005 - ASHP R UGGLES , P H .D., is Associate Director Medical Writing, Medical Af- fairs; L
ORETTA L. N IELSEN , P H .D., is Senior Medical Writer, Medical Affairs; M ARK
S. F INEMAN , BS, is Senior Director, Clinical Affairs; and A LAIN D. B ... Cited by 139 - Related articles - All 5 versions
MA Nauck, S Duran, D Kim, D Johns, J … - Diabetologia, 2007 - Springer Abstract Aims/hypothesis The aim of this 52-week, open-label, non- inferiority
trial was to compare the safety and efficacy of exenatide (an incretin mimetic)
with that of biphasic insulin aspart. Materials and methods Patients on ... Cited by 132 - Related articles - BL Direct - All 4 versions
